Clinical Research, Pharma & Healthcare FinancingENHERTU® EU Approval: First HER2 Therapy for HR+ Metastatic BCBusiness WireApril 4, 2025April 7, 2025 by Business WireApril 4, 2025April 7, 2025020 Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of...
